RFVIIIFc: Phase II/III started

The companies began the open-label, international, pivotal Phase II/III A-LONG trial to evaluate a low- and high-dose prophylaxis regimen of IV rFVIIIFc and rFVIIIFc for use on demand in 150 previousl...